Reversion of β-Cell Autoimmunity Changes Risk of Type 1 Diabetes: TEDDY Study | Zendy

Kendra Vehik | Zendy; Kristian Lynch | Zendy; Desmond Schatz | Zendy; Beena Akolkar | Zendy; William Hagopian | Zendy; Marian Rewers | Zendy; JinXiong She | Zendy; Olli Simell | Zendy; Jorma Toppari | Zendy; AnetteG. Ziegler | Zendy; Åke Lernmark | Zendy; Ezio Bonifacio | Zendy; Jeffrey P. Krischer | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Reversion of β-Cell Autoimmunity Changes Risk of Type 1 Diabetes: TEDDY Study

Author(s) -

Kendra Vehik,

Kristian Lynch,

Desmond Schatz,

Beena Akolkar,

William Hagopian,

Marian Rewers,

JinXiong She,

Olli Simell,

Jorma Toppari,

AnetteG. Ziegler,

Åke Lernmark,

Ezio Bonifacio,

Jeffrey P. Krischer

Publication year - 2016

Publication title -

diabetes care

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.636

H-Index - 363

eISSN - 1935-5548

pISSN - 0149-5992

DOI - 10.2337/dc16-0181

Subject(s) - autoantibody , medicine , type 1 diabetes , immunology , diabetes mellitus , cohort , autoimmunity , seroconversion , type 2 diabetes , antibody , endocrinology

β-Cell autoantibodies are a feature of the preclinical phase of type 1 diabetes. Here, we asked how frequently they revert in a cohort of children at risk for type 1 diabetes and whether reversion has any effect on type 1 diabetes risk.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research